AbCellera Investor Presentation Deck
EARNINGS CALL SUMMARY
Q3 2023 BUSINESS UPDATE
COPYRIGHT © ABCELLERA
1
EARNINGS CALL SUMMARY
Note: This document contains a condensed summary of AbCellera's 2023-11-02 earnings call. It should be read in conjunction with,
and in the context of, the contents of the call itself.
AbCellera achieves a
significant company
milestone, advancing two
assets, ABCL575 and
ABCL635, from AbCellera-led
programs into IND-enabling
studies.
●
ABCL575 targets the OX40 ligand (OX40L) and has been designed as a potential best-in-class therapy for
atopic dermatitis and other indications in autoimmunity and inflammation.
ABCL575 was discovered as part of AbCellera's 2021 co-development collaboration with EQRx.
AbCellera took ownership of the program in Q3 2023.
ABCL575 has been designed with potency, PK, and developability to enable less-frequent dosing than
benchmark molecules.
●
●
●
ABCL635 is the first pipeline asset from the company's GPCR and lon Channel platform.
ABCL635 hits an undisclosed target with an indication in metabolic and endocrine disorders.
Overall market estimated at over $2 billion in annual sales.
●
●
AbCellera anticipates potential IND submissions for ABCL575 and ABCL635 in 2025.
AbCellera anticipates additional development candidates from AbCellera-led programs to advance into
late-stage preclinical and IND-enabling studies in 2024 and 2025.View entire presentation